The Lancet HIV

ISSNs: 2405-4704

Elsevier

Journal

Publications

  1. 2018
  2. Risks and benefits for use of dolutegravir-based antiretroviral drug regimens in sub Saharan Africa: a modelling study

    Phillips, A., Venter, F., Havlir, D., Pozniak, A., Kuritzkes, D., Wensing, A., Lundgren, J., De Luca, A., Pillay, D., Mellors, J., Cambiano, V., Bansi-Matharu, L., Nakagawa, F., Kalua, T., Jahn, A., Apollo, T., Mugurungi, O., Clayden, P., Gupta, R., Barnabas, R. & 4 othersRevill, P., Cohn, J., Bertagnolio, S. & Calmy, A., 29 Nov 2018

    Article in The Lancet HIV

  3. 2014
  4. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis

    Phillips, A., Cambiano, V., Miners, A., Revill, P., Pillay, D., Lundgren, J., Bennett, D., Raizes, E., Nakagawa, F., De Luca, A., Vitoria, M., Barcarolo, J., Perriens, J., Jordan, M. & Bertagnolio, S., Nov 2014

    Article in The Lancet HIV

  5. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population

    Miners, A., Phillips, A., Kreif, N., Rodger, A., Speakman, A., Fisher, M., Anderson, J., Collins, S., Hart, G., Sherr, L. & Lampe, FI. C., 2014

    Article in The Lancet HIV

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations